Eris Biotech
ActiveOur drugs engage the immune system to fight tumors
About
We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
Founders · 2
PhD in Immunology from Dartmouth College. Engineered many novel cancer immunotherapies. We build cancer drugs that reawaken the immune system to fight cancer for you. No tox, no side effects, and most importantly -- no cancer.
PhD in microbiology and molecular biology with an emphasis in cancer immunology, working on developing drugs that reawaken the immune system to fight cancer. First-generation immigrant from Peru. Mom of two boys.
Launch
Tumors turn OFF the immune system. Our drugs turn the immune system ON to kill cancer.
Eris Biotech develops small-molecule drugs that prevent tumors from releasing immune-suppressing vesicles, thereby restoring immune surveillance and enabling the body's immune system to fight cancer. They announce a first-in-class approach starting with mesothelioma, aiming to awaken the immune system rather than directly killing cancer cells.
From the original launch (Feb 2024) — may be outdated.
Related startups
Enabling Tissue Targeting of Therapies
Targeting the Tumor Ecosystem to address cancer drug resistance.
